Author:
Morla-Barcelo Pere Miquel,Laguna-Macarrilla David,Cordoba Octavi,Matheu Gabriel,Oliver Jordi,Roca Pilar,Nadal-Serrano Mercedes,Sastre-Serra Jorge
Abstract
Abstract
Background
Early-stage invasive ductal carcinoma displays high survival rates due to early detection and treatments. However, there is still a chance of relapse of 3–15% after treatment. The aim of this study was to uncover the distinctive transcriptomic characteristics and monitoring prognosis potential of peritumoral tissue in early-stage cases.
Methods
RNA was isolated from tumoral, peritumoral, and non-tumoral breast tissue from surgical resection of 10 luminal early-stage invasive ductal carcinoma patients. Transcriptome expression profiling for differentially expressed genes (DEGs) identification was carried out through microarray analysis. Gene Ontology and KEGG pathways enrichment analysis were explored for functional characterization of identified DEGs. Protein-Protein Interactions (PPI) networks analysis was performed to identify hub nodes of peritumoral tissue alterations and correlated with Overall Survival and Relapse Free Survival.
Results
DEGs closely related with cell migration, extracellular matrix organization, and cell cycle were upregulated in peritumoral tissue compared to non-tumoral. Analyzing PPI networks, we observed that the proximity to tumor leads to the alteration of gene modules involved in cell proliferation and differentiation signaling pathways. In fact, in the peritumoral area were identified the top ten upregulated hub nodes including CDK1, ESR1, NOP58, PCNA, EZH2, PPP1CA, BUB1, TGFBR1, CXCR4, and CCND1. A signature performed by four of these hub nodes (CDK1, PCNA, EZH2, and BUB1) was associated with relapse events in untreated luminal breast cancer patients.
Conclusions
In conclusion, our study characterizes in depth breast peritumoral tissue providing clues on the changes that tumor signaling could cause in patients with early-stage breast cancer. We propose that the use of a four gene signature could help to predict local relapse. Overall, our results highlight the value of peritumoral tissue as a potential source of new biomarkers for early detection of relapse and improvement in invasive ductal carcinoma patient’s prognosis.
Publisher
Springer Science and Business Media LLC
Reference61 articles.
1. De Polo J, Invasive Ductal Carcinoma (IDC).: Grade, Symptoms & Diagnosis. In: Breastcancer.org. https://www.breastcancer.org/types/invasive-ductal-carcinoma. Accessed 4 oct 2023.
2. Zhao H. The prognosis of invasive ductal carcinoma, lobular carcinoma and mixed ductal and lobular carcinoma according to molecular subtypes of the breast. Breast Cancer. 2021;28:187–95.
3. Breast Cancer Recurrence. Rates, Signs & Treatment. https://my.clevelandclinic.org/health/diseases/8328-breast-cancer-recurrence. Accessed 4 oct 2023.
4. Shachar SS, Leviov M, Yerushalmi R, et al. Second breast cancer: recurrence score results, clinicopathologic characteristics, adjuvant treatments, and outcomes-exploratory analysis of the Clalit registry. NPJ Breast cancer. 2023;9:79.
5. Song R, Lee D-E, Lee E-G, et al. Clinicopathological Factors Associated with Oncotype DX Risk Group in patients with ER+/HER2- breast Cancer. Cancers (Basel). 2023;15:4451.